Nuveen
ROIV icon

Nuveen’s Roivant Sciences ROIV Stock Holding History

Nuveen’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.7M Buy
1,970,504
+15,458
+0.8% +$457K 0.02% 536
2026
Q1 		$54.2M Sell
1,955,046
-294,821
-13% -$7.57M 0.01% 611
2025
Q4 		$48.8M Sell
2,249,867
-43,119
-2% -$851K 0.01% 652
2025
Q3 		$34.7M Buy
2,292,986
+11,460
+0.5% +$142K 0.01% 804
2025
Q2 		$25.7M Sell
2,281,526
-888,760
-28% -$9.63M 0.01% 942
2025
Q1 		$32M Buy
3,170,286
+156,753
+5% +$1.7M 0.01% 837
2024
Q4 		$35.7M Sell
3,013,533
-171,939
-5% -$2.03M 0.01% 828
2024
Q3 		$36.8M Buy
3,185,472
+17,492
+0.6% +$199K 0.01% 816
2024
Q2 		$33.5M Buy
3,167,980
+812,468
+34% +$8.9M 0.01% 828
2024
Q1 		$24.8M Sell
2,355,512
-18,403
-0.8% -$198K 0.01% 1040
2023
Q4 		$26.7M Buy
2,373,915
+940,315
+66% +$9.16M 0.01% 961
2023
Q3 		$16.7M Buy
1,433,600
+697,011
+95% +$7.88M 0.01% 1139
2023
Q2 		$7.42M Buy
+736,589
New +$6.59M ﹤0.01% 1681

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Nuveen's ROIV Position: Q2 2026 in Review

Nuveen increased its Roivant Sciences (ROIV) stake by 0.79% in Q2 2026, buying an estimated $457K and bringing the position to 1,970,504 shares worth $69.7M. The position accounts for 0.02% of the portfolio, ranked #536.

Nuveen first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Nuveen held 1,970,504 shares of Roivant Sciences worth $69.7M as of Q2 2026.
  • Nuveen bought 15,458 Roivant Sciences shares in Q2 2026, an estimated $457K.
  • Roivant Sciences made up 0.02% of Nuveen's portfolio in Q2 2026, its #536 holding.
  • Nuveen first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.